Developmental Funds

发展基金

• 批准号: 10625759
• 负责人: Jonathan D. Licht
• 金额: $ 30.5万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10625759
• 关键词: Abbreviations; Address; Advocacy; Aging; Award; Basic Cancer Research; Biology; Biomedical Research; Blood; CCL21 gene; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Catchment Area; Clinical; Clinical Research; Clinical Trials; Collaborations; Communication; Development; Direct Costs; Disease; Enrollment; Epigenetic Process; Extramural Activities; Faculty; Florida; Fostering; Funding; Funding Mechanisms; Grant; Growth; Health; Immune response; Immunotherapy; Institution; Intervention; Intervention Trial; Investments; Last Name; Leadership; Lung; Malignant Neoplasms; Measures; Medicine; Mission; NCI Center for Cancer Research; NCI-Designated Cancer Center; Outcome; Peer Review; Policies; Population; Population Sciences; Productivity; Publications; Qualifying; RNA; Research; Research Personnel; Research Proposals; Role; Science; Site; Solid Neoplasm; Source; Strategic Planning; Testing; Time; Tobacco Use Cessation; Underrepresented Minority; Universities; Woman; anticancer research; cancer health disparity; clinical care; clinical investigation; college; flexibility; host microbiota; innovation; investigator-initiated trial; member; novel; participant enrollment; patient engagement; population based; prevent; programs; recruit; targeted treatment; translational scientist; treatment response; tumorigenesis

DEVELOPMENTAL FUNDS: ABSTRACT Cancer Center Support Grant (CCSG) Developmental Funds are critical to fulfill the mission of the University of Florida Health Cancer Center (UFHCC). Developmental Funds foster innovative research and strategic recruitment aligned with the Center's strategic initiatives. Since 2016, the UFHCC has collaborated across the University of Florida in the internal and external recruitment of 58 new UFHCC members (45 new to UF), of which 39 (67%) are early-stage investigators (ESIs), 26 (45%) are women, and 10 (17%) are underrepresented minorities. Faculty were recruited into 8 of the colleges that contribute members to the UFHCC. Of these recruits, 20 are members of Mechanisms of Oncogenesis, 19 are members of Cancer Therapeutics and Host Response, and 19 are in Cancer Control and Population Sciences, showing even distribution across the programs. UFHCC committed a total of $29.9M in start-up support for all recruitment, with $14.4M expended to date. These new UFHCC members have already made significant contributions to the center in terms of collaborative programmatic and multi-institutional research, publications, and interventional clinical trials. Importantly, since joining UF, these new members have obtained 56 new peer-reviewed extramural grants totaling $39M (direct costs), of which $14.8M (~38%) is from NCI. The total extramural funding, including transferred grants, attributed to these recruits is $52.4M (direct costs), with $24.2M (46%) awarded by the NCI. The return on investment on UFHCC recruitment expenses to date relative to all extramural peer-reviewed funding (direct costs) attributed to recruits is >3.6:1. Since 2016, the UFHCC Pilot and Exploratory Study Proposals received 183 proposals for review, with 33% approved for funding. Outcomes of projects awarded between 2016 and 2020, for which enough time had passed to assess impact ($3M of pilot funding), included 159 publications and $20M (direct costs, for all award years) in new extramural peer-reviewed funding, a return on investment ratio of ~6.7:1. Since 2016, Developmental Funds have assisted in the expansion of the UFHCC funding portfolio. With the new recruits, total cancer-relevant funding increased from $21M in 2016 to $32.6M in 2021 (up 55%) direct costs, NCI funding increasing from $9.6M to $13.2M (up 37%) direct costs. The overall research productivity of the UFHCC increased from 369 publications in 2016 to 641 in 2021 (up 1.7-fold). The number of publications with impact ≥10 went from 59 in 2016 to 95 in 2021. Since 2016, Developmental Funds also supported the recruitment of 18 members who developed novel interventional IITs. In 2016, accruals to IITs accounted for 70% of participants enrolled in trials (23% of treatment accruals). In 2021, IIT accruals accounted for 91% of enrollments (59% of treatment). Interventional trial accruals increased from 515 in 2016 to 1,748 in 2021 (up 3.4-fold). Treatment accruals increased from 138 in 2016 to 299 in 2021 (up 2.2-fold). Developmental funds will be used for pilot grants to encourage innovative transdisciplinary science on cancers relevant to the catchment area, and recruitment of highly qualified and diverse new members across the 3 research programs.

发展基金：摘要 癌症中心支持补助金 (CCSG) 发展基金对于履行大学的使命至关重要 佛罗里达健康癌症中心 (UFHCC)。发展基金促进创新研究和战略 招聘符合中心的战略举措。自 2016 年以来，UFHCC 在各个领域开展了合作 佛罗里达大学在内部和外部招聘58名新UFHCC会员（45名新加入UF）， 其中 39 名 (67%) 是早期研究人员 (ESI)，26 名 (45%) 是女性，10 名 (17%) 代表性不足 少数民族。为 UFHCC 贡献成员的 8 所学院招募了教员。这些新兵中， 20 名是肿瘤发生机制的成员，19 名是癌症治疗和宿主反应的成员， 19 个属于癌症控制和人口科学，在各个项目中分布均匀。 UFHCC 承诺为所有招聘提供总计 2,990 万美元的启动支持，迄今为止已支出 1,440 万美元。这些新 UFHCC 成员已经在合作方面为中心做出了重大贡献 计划性和多机构研究、出版物和介入性临床试验。重要的是，自从 加入佛罗里达大学后，这些新成员获得了 56 项新的同行评审的校外资助，总额达 3900 万美元（直接 成本），其中 1480 万美元（约 38%）来自 NCI。外部资金总额，包括转移补助金，归属于 向这些新招募人员支付的费用为 5240 万美元（直接成本），其中 2420 万美元（46%）由 NCI 奖励。投资回报率 迄今为止 UFHCC 招聘费用相对于所有外部同行评审资金（直接费用）归因于 新兵比例>3.6:1。自2016年以来，UFHCC试点和探索性研究提案收到了183份提案 审查，33%获得资助。 2016 年至 2020 年间授予的项目成果，其中 已经过去了足够的时间来评估影响（300 万美元的试点资金），包括 159 份出版物和 2000 万美元（直接 费用（所有奖励年份））在新的外部同行评审资金中，投资回报率约为 6.7:1。自从 2016年，发展基金协助扩大了UFHCC的资金组合。随着新 癌症相关资金总额从 2016 年的 2100 万美元增加到 2021 年的 3260 万美元（增长 55%）， NCI 资助的直接成本从 960 万美元增加到 1320 万美元（增长 37%）。整体研究生产力 UFHCC 的出版物从 2016 年的 369 篇增加到 2021 年的 641 篇（增长了 1.7 倍）。出版物数量 影响≥10从2016年的59个增加到2021年的95个。自2016年以来，发展基金还支持招聘 18 名开发新型介入 IIT 的成员。 2016年，应计个人所得税占总收入的70% 参加试验的参与者（治疗应计费用的 23%）。 2021年，应计个人所得税占入学人数的91% （治疗的 59%）。干预试验应计项目从 2016 年的 515 项增加到 2021 年的 1,748 项（增长 3.4 倍）。 治疗应计人数从 2016 年的 138 人增加到 2021 年的 299 人（增加了 2.2 倍）。发展资金将用于 提供试点赠款，以鼓励与流域相关的癌症的创新跨学科科学，以及 在 3 个研究项目中招募高素质且多样化的新成员。